Skip to main content

Table 2 Chromosomal translocations and fusion proteins in hematologic malignancies involving ALK gene

From: Novel ALK inhibitors in clinical use and development

Disease Chromosomal rearrangement Fusion protein Frequency (%) Reference
ALCL t(2;5)(p23;q35) NPM-ALK 75-80 [9]
  t(2;17)(p23;q25) ALO17-ALK <1 [34]
  t(2;3)(p23;q21) TFG-ALK 2 [48]
  t(2;X)(p32;q11-q12) MSN-ALK <1 [44]
  t(1;2)(q25;p23) TPM3-ALK 12-18 [22]
  t(2;19)(p23;p13) TPM4-ALK <1 [30]
  inv(2)(p23;q35) ATIC-ALK 2 [31]
  t(2;22)(p23;q11.2) MYH9-ALK <1 [37]
  t(2;17)(p23;q23) CLTCL-ALK 2 [58]
DLBCL t(2;5)(p23;q35) NPM-ALK ND [10]
  t(2;17)(p23;q23) CLTC1-ALK ND [41]
  t(2;5)(p23.1;q35.3) SQSTM1-ALK ND [54]
  ins(4)(2;4)(p23;q21) SQSTM1-ALK ND [56]
  t(2;4)(p24;q21) SEC31A-ALK ND [45]
HL t(2;5)(p23;q35) NPM-ALK ND [1]
  1. ALCL; anaplastic large cell lymphoma, DLBCL; diffuse large B cell lymphoma; HL: Hodgkin lymphoma; ND; not determined.